Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 1st International Workshop on Differentiation Syndrome (iwDS) took place in New York City, NY, on 6-7 November 2025, where the world’s leading clinical and translational researchers discussed the latest advances in differentiation syndrome. The iwDS 2025 Workshop was supported by Johnson & Johnson (Silver), Kura Oncology (Silver), Syndax (Silver), Sumitomo Pharma (Bronze). Supporters have no influence over the production of content.
iwDS 2025
1st International Workshop on Differentiation Syndrome
06–07 November 2025 | New York, NY
The 1st International Workshop on Differentiation Syndrome (iwDS) took place in New York City, NY, on 6-7 November 2025, where the world’s leading clinical and translational researchers discussed the latest advances in differentiation syndrome. The iwDS 2025 Workshop was supported by Johnson & Johnson (Silver), Kura Oncology (Silver), Syndax (Silver), Sumitomo Pharma (Bronze). Supporters have no influence over the production of content.
History of differentiation syndrome
Reflections on the initial recognition of differentiation syndrome with ATRA
Farhad Ravandi The University of Texas MD Anderson Cancer Center, Houston, TX, United States
History of differentiation syndrome recognition with ATRA and arsenic trioxide in Europe and European trials
Miguel Sanz University of Valencia, Valencia , Spain
Biology and pathogenesis of differentiation syndrome
What are the pathogenetic mechanisms that cause differentiation syndrome?
Stéphane de Botton Gustave Roussy, Paris, France
How to design clinical and translational studies to identify the underlying mechanisms of DS better
Alice Mims The Ohio State University, Columbus, Ohio, United States
Clinical manifestations of differentiation syndrome
Differentiation syndrome in APL with ATRA/arsenic
Martin Tallman Memorial Sloan Kettering Cancer Center, New York City, NY, United States
A double-edged sword? Differentiation syndrome and IDH inhibitors
Amir Fathi Massachusetts General Hospital Cancer Center, Boston, MA, United States
Is there differentiation syndrome with other agents for AML? (BRG/BRM, FLT3, HMA)
Alexander Perl University of Pennsylvania, Philadelphia, PA, United States
Coming soon
Differentiation syndrome with menin inhibitors
Eunice Wang Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Are there differences in the clinical manifestations of differentiation syndrome between differentiation agents/different subtypes of AML?
Ghayas Issa The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Perspectives on differentiation syndrome: diagnosis, regulatory, and industry
Should we create a standardized diagnostic criteria/algorithm for DS?:
Ghayas Issa The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Novel therapies and the potential to counter differentiation syndrome
Kate Yen Auron Therapeutics, Wellesley Hills, MA, United States
Coming soon
Regulatory thoughts on differentiation syndrome
Ashley Woods U.S. Food and Drug Administration, Silver Spring, Maryland, United States
Treatment of differentiation syndrome
Are steroids the best way to treat active differentiation syndrome?
Justin Watts University of Miami, Miami, FL, United Kingdom
Novel agents in the treatment of differentiation syndrome
Yannis Valtis Memorial Sloan Kettering Cancer Center, New York, NY, United States
Combining differentiating agents – double trouble or smart strategy?
Uma Borate Ohio State University, Columbus, OH, United States
Prevention of differentiation syndrome
History of using steroid prophylaxis for APL
Yasmin Abaza Northwestern University, Chicago, IL, United States
What can we learn from steroid prophylaxis to prevent DS in APL?
Joshua Zeidner UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NY, United States
